New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,355.43 3.78 +0.28%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company (LLY) Earnings & Analysis

Updated · Covers results through Q3 FY2026 · Earnings call · Latest filing 10-Q filed Oct 29, 2026 · How this is made

Latest quarter

Eli Lilly reported Q3 FY2026 revenue of $24.4 billion, above the $22.1 billion consensus and up 38.6% from a year earlier. Adjusted earnings per share were $7.48, above the $5.38 consensus.

Lilly’s filing attributed revenue growth primarily to higher volumes, partly offset by lower realized prices, with Mounjaro and Zepbound driving both trends. The company said combined quarterly sales of the two medicines reached $16.1 billion. The filing said Mounjaro’s growth outside the U.S. was driven by volume, while its inclusion on China’s reimbursement list reduced realized prices.

Gross margin rose to 83.9% from 82.9% a year earlier; Lilly attributed the increase mainly to production costs and product mix, partly offset by lower prices. Operating margin fell to 36.5% from 43.9%. The filing said higher acquired research charges and operating expenses partly offset the effect of higher gross margin on earnings.

Free cash flow was $8.2 billion, compared with $6.7 billion a year earlier. CFO Lucas Montarce said quarterly revenue included approximately $900.0 million from items including milestones and changes in rebate and discount estimates.

Q3 FY2026 Q3 FY2025 Change
Revenue $24.4 billion $17.6 billion 38.6%
Diluted EPS $7.22 $6.21 16.3%
Gross margin 83.9% 82.9% 1.0 percentage point
Operating margin 36.5% 43.9% −7.4 percentage points
Free cash flow $8.2 billion $6.7 billion 21.8%
Against the consensus Reported Consensus Result
Adjusted EPS $7.48 $5.38 Beat by 39.0%
Revenue $24.4 billion $22.1 billion Beat by 10.4%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

CEO David Ricks said the Medicare GLP-1 Bridge program had expanded access to obesity medicines for seniors, with more than 500,000 people filling a Lilly prescription through it since launch. Asked about the program, Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, said 80.0% of people receiving treatment through Bridge had not previously been on therapy. He said lower out-of-pocket costs helped patients stay on treatment, adding that “a low out of pocket helps with that friction point.”

CFO Lucas Montarce said U.S. revenue growth was driven by Zepbound and Mounjaro volumes, partly offset by lower prices. He said favorable product mix and production costs supported the gross margin, while lower realized prices provided an offset. Montarce also said spending on research and development and promotion rose as Lilly invested in its pipeline and product launches.

Analysts asked whether incretin growth had been pulled forward. Montarce replied that Lilly was still reaching a small share of potential patients and said, “we are still scratching the surface on the number of patients that we can reach.” Asked about competition and pricing outside the U.S., Lilly International president Patrik Jonsson said the company had maintained its share and continued to grow following generic launches in several markets.

On Foundayo, Jonsson said international launches were in line with expectations and that oral medicines were bringing new patients into the market. Yuffa said U.S. awareness and provider adoption had improved, although he expected adherence to oral medicines to be lower than for weekly injections.

Ricks said Lilly had begun building manufacturing facilities in Texas and Virginia. Looking ahead, Montarce said Lilly expected U.S. incretin volume growth and a full year of Bridge access in 2027, while Yuffa expected commercial access to remain relatively stable.

Guidance

Lilly raised its FY2026 revenue guidance and now expects $91.0 billion to $92.0 billion. It revised its non-GAAP earnings-per-share outlook to $35.00 to $36.00; Montarce said the outlook reflected updated acquired research charges.

For 2027, Montarce said Lilly expects volume growth to more than offset a net realized price headwind. He said the company would provide its 2027 financial guidance on its Q4 call.

Metric For Guide Previous guide Change
Units FY2027 Eli Lilly expects volume growth to more than offset a net realized price headwind in FY2027. — —
Market share, Mounjaro International FY2027 Eli Lilly expects Mounjaro to maintain its market leadership outside the U.S. in FY2027. — —
Market size, US Incretin Market FY2027 Eli Lilly expects sustained volume growth in the U.S. incretin market in FY2027. — —
EPS, non-GAAP FY2026 $35.00–$36.00 $35.50–$36.50 Cut
Operating margin, non-GAAP FY2026 52.5% — New
Revenue FY2026 $91.0 billion–$92.0 billion $85.0 billion–$87.0 billion Raised
Tax rate, non-GAAP FY2026 19.0%–20.0% — New
EPS FY2026 $35.50–$37.00 — New
Operating margin FY2026 47.0%–48.5% — New